New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.

The study (the SURPASS-PEDS trial), by Dr Tamara Hannon, Division of Pediatric Endocrinology and Diabetology, Indiana University School of Medicine, Indiana University School of Medicine, Indianapolis, USA, and colleagues is presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in The Lancet. The study is sponsored by Eli Lilly and company, the manufacturer of tirzepatide.

Cervical cancer is the fourth most common cancer among women globally, according to the World Health Organization. It accounted for 660,000 new cases and 350,000 deaths in 2022.

Screening, along with early detection and treatment, can greatly improve a patient’s chances of survival. But in low- to middle-income countries, many women are not being screened, and they’re disproportionately dying from the disease.

In new research from Texas McCombs, Anima Nivsarkar, a doctoral student in marketing, uncovers a powerful tool to boost screening: trust. When messages are delivered by trusted and credible sources such as doctors and peers, they increase the likelihood that women will seek potentially life-saving exams.

JACC, the flagship journal of the American College of Cardiology, and the University of Washington's Institute for Health Metrics and Evaluation are hosting a UNGA side event to discuss data from the Global Burden of Disease (GBD) 2023 study, the largest and most comprehensive source of health data with nearly 16,500 expert contributors in 168 countries.